Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
Perilli M, Celenza G, De Santis F, Pellegrini C, Forcella C, Rossolini GM, Stefani S, Amicosante G. Perilli M, et al. Among authors: forcella c. Antimicrob Agents Chemother. 2008 Mar;52(3):915-9. doi: 10.1128/AAC.01028-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160520 Free PMC article.
Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy.
Gravina GL, Marampon F, Sanità P, Festuccia C, Forcella C, Scarsella L, Jitariuc A, Vetuschi A, Sferra R, Colapietro A, Carosa E, Dolci S, Lenzi A, Jannini EA. Gravina GL, et al. Among authors: forcella c. Oncotarget. 2017 Nov 30;8(69):113792-113806. doi: 10.18632/oncotarget.22776. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371946 Free PMC article.
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Ferrara MG, Martini M, D'Argento E, Forcella C, Vita E, Di Noia V, Sperduti I, Bilotta M, Ribelli M, Damiano P, Cannella A, Stefani A, Pilotto S, Carbone C, Piro G, Milella M, Tortora G, Bria E. Ferrara MG, et al. Among authors: forcella c. Clin Lung Cancer. 2021 Jul;22(4):351-360. doi: 10.1016/j.cllc.2020.12.008. Epub 2021 Feb 6. Clin Lung Cancer. 2021. PMID: 33558194
12 results